AnaptysBio, Inc. (ANAB) Stock Price, Financial Report, & Fundamental Analysis
NASDAQ:ANABAnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.
(0.7)
AnaptysBio, Inc. Fundamental Analysis
Strength
| Analysis | # |
|---|---|
RevenueANAB has positive revenue for last 5 years |
Weakness
| Analysis | # |
|---|---|
Market CapSmall market capitalization. Market capitalization is less than 2bn USD |
|
Revenue GrowthANAB has never had growing revenue. |
|
Net Income GrowthANAB has never had growing net income. |
|
Price to Book (PBV) RatioOvervalued price-to-book. ANAB stock price is overvalued by more than 2x the price-to-book value. |
|
Net IncomeANAB never has positive net income for 2 years. |
|
Debt-Equity Ratio (DER)ANAB debt is 1.23x it's equity. |
|
Dividend YieldANAB has low dividend yield (0%). |
|
Return of AssetsANAB has low return of asset (-21.8%). |
|
Return of EquityANAB has low return of equity (-42.5%). |
|
Return of Invested CapitalANAB has low ROIC. |
Competitors
AnaptysBio, Inc. Financials
Financial statements are written records that convey the business activities and the financial performance of a company. Financial statements include the balance sheet, income statement, and statement of cash flow.
Income Statement
Also known as the profit and loss (P&L) statement or the statement of revenue and expense, the income statement primarily focuses on the company’s revenue and expenses during a particular period.
- Revenue
- 63,175,000 USD
- Cost
- 0 USD
- Net Income
- -57,796,000 USD
- Profit Margin
- -91.49%
Cashflow Statement
A cash flow statement is a financial statement that provides aggregate data regarding all cash inflows a company receives from its ongoing operations and external investment sources. It also includes all cash outflows that pay for business activities and investments during a given period.
- Free Cash Flow
- -45,905,000 USD
Balance Sheet
Liquidity & Solvency
Solvency refers to an company's capacity to meet its long-term financial commitments. Liquidity refers to an company's ability to pay short-term obligations. The term also refers to a company's capability to sell assets quickly to raise cash.
Short Term Liabilities
| Quick Ratio | 2108.65% |
Long Term Liabilities
| Liquidity/Current Ratio | 2138.56% |
Dividend
| Dividend Yield | 0% |
| Dividend Payout Ratio (DPR) | 0% |
| Dividend Payout Ratio (DPR) | 0% |
| Dividend per Share | 0,00 USD |
Financial Ratios
| Price to Earning (PER) | -10.9x |
| Price to Earning-Growth (PEG) | 0x |
| Price to Book Value (PBV) | 0x |
| Liquidity/Current Ratio | 2138.56% |
| Cash Ratio | 277.96% |
| Debt Ratio | 55.11% |
| Debt-Equity Ratio (DER) | 122.79% |
| Net Profit Margin (NPM) | -3003.32% |
| Return of Assets (ROA) | -21.8% |
| Return of Equity (ROE) | -42.5% |
| Return on Capital Employed (ROCE) | -20.14% |
| Days of Sales Outstanding (DSO) | 95.92 |
| Days of Inventory Outstanding (DIO) | 0 |
| Days Payable Outstanding (DPO) | 0 |
| Operating Cycle (OC) | 0 |
| Cash Conversion Cycle (CCC) | 0 |
AnaptysBio, Inc. Executives
CEO
- CEO Name
- Mr. Hamza Suria
Management
AnaptysBio, Inc. Profile
About AnaptysBio, Inc.
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Additional Information
- Company name
- AnaptysBio, Inc.
- Symbol
- NASDAQ:ANAB
- Exchange
- NASDAQ Global Select
- Industry
- Biotechnology
- Sector
- Healthcare
- Address
-
10421 Pacific Center Ct Ste 200
San Diego
CALIFORNIA
US
92121-5801 - Website
- https://www.anaptysbio.com